Product Name: AF9 Antibody
Species Reactivity: Human
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:50~100
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 63 kDa
Immunogen: This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).
Host Species: Rabbit
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Physical State: Liquid
CAS NO.: 23599-69-1
Product: Norisoboldine
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 2 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Protein AF-9, ALL1-fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, YEATS domain-containing protein 3, MLLT3, AF9, YEATS3
Accession NO.: P42568
Protein Ino: 215273971
Official Symbol: MLLT3
Geneid: 4300
Background: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9;11)(p22;q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified; BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.
PubMed ID:http://aac.asm.org/content/52/5/1647.abstract
